健康发展与政策研究2024，Vol.27Issue(4)：331-338,344,9.DOI:10.12458/HDPR.202403011
治疗急性缺血性脑卒中的3种创新药经济性、可及性对比
Comparison of the economic and accessibility of three innovative drugs in the treatment of acute ischemic stroke
摘要
Abstract
Objective To compare the economic aspects and accessibility of three innovative brain cytoprotective drugs(Urinary Kallidinogenase Injection,Edaravone dexborneol Injection,and dl-3-n-butylphthalide Injection)in acute ischemic stroke,providing a basis for the rational allocation of healthcare resources.Methods For economic evaluation,a decision-tree model was constructed and a cost-utility analysis was performed from the perspective of China's healthcare system.For accessibility,data were collected through hospital surveys and literature reviews to describe the availability and affordability of the three drugs in Jiangsu,Zhejiang and Shanghai.Results In terms of cost-effectiveness,the total direct medical costs within 90 days for Urinary Kallidinogenase Injection,Edaravone dexborneol Injection,and dl-3-n-butylphthalide Injection were ¥19514.68,¥19575.47,and ¥20264.07,respectively,with corresponding utilities of 0.1746 QALYs,0.1822 QALYs,and 0.1799 QALYs.The use of Edaravone dexborneol Injection compared to Urinary Kallidinogenase Injection resulted in an incremental cost-effectiveness ratio of ¥8010.15/QALY,which is less than the average GDP per capita,indicating better cost-effectiveness.Compared to dl-3-n-butylphthalide Injection,Edaravone dexborneol Injection was more cost-effective and had higher utility.Sensitivity analysis showed that results are robust.The average hospital availability rates for Urinary Kallidinogenase Injection,Edaravone dexborneol Injection,and dl-3-n-butylphthalide Injection were 59.8%,84.4%,and 95.9%in Shanghai,Zhejiang and Jiangsu,respectively,with no statistically significant differences between regions.The total treatment costs of the three drugs over 90 days accounted for 10.6%to 15.6%of the average family annual income,not resulting in catastrophic health expenditure.Among these,Urinary Kallidinogenase Injection had the lowest cost.Conclusions Among the three innovative brain cytoprotective therapies,Urinary Kallidinogenase Injection has the lowest cost,while Edaravone dexborneol Injection is the most cost-effective.Dl-3-n-butylphthalide Injection has the highest availability in Shanghai,Zhejiang and Jiangsu.关键词
脑细胞保护/脑卒中/药物经济学/可及性Key words
brain cytoprotection/stroke/pharmacoeconomics/accessibility分类
医药卫生引用本文复制引用
蔡彩平,丁海霞..治疗急性缺血性脑卒中的3种创新药经济性、可及性对比[J].健康发展与政策研究,2024,27(4):331-338,344,9.基金项目
江苏省医院协会医院管理创新专项研究课题(JSYGY-2021-JY20) （JSYGY-2021-JY20）
